摘要
目的:了解2018—2022年甘肃省不同级别医疗机构糖尿病治疗药物使用情况,为相关部门控制糖尿病药品费用提供参考。方法:利用结构指数分解的方法,对2018—2022年甘肃省不同级别医疗机构糖尿病治疗药物的用药金额、价格、数量及用药结构等进行分析。结果:2018—2022年,甘肃省糖尿病治疗药物用药金额、用药频度(DDDs)的年均增长率为9.35%(从3.14亿元增至4.49亿元)、36.05%(从2.58×10^(8)增至8.84×10^(8)),其中一级医疗机构用药金额年均增长率最高,为17.98%(从0.16亿元增至0.31亿元),三级医疗机构用药金额年均增长率最低,为7.85%(从1.70亿元增至2.30亿元);5年间,各级医疗机构糖尿病治疗药物在用药结构指数上有较大差异。结论:甘肃省糖尿病治疗药物的总用药金额及DDDs增速有差异,各级医疗机构糖尿病治疗药物使用类别各有侧重。与2018年相比,2022年各级医疗机构使用高价药比例升高,一级医疗机构最为明显,在用药规范性上仍有较大的上升空间。应继续推进临床合理用药,有效控制药品费用的增长。
OBJECTIVE:To investigate the drug use of diabetes in different levels of medical institutions in Gansu from 2018 to 2022,so as to provide reference for relevant departments to control the cost of diabetes drugs.METHODS:Method of structural index decomposition was used,the consumption sum,price,quantity and drug structure of drug use for diabetes in different levels of medical institutions in Gansu from 2018 to 2022 were analyzed.RESULTS:From 2018 to 2022,the average annual growth rates of the consumption sum and defined daily dose system(DDDs)of diabetes drugs in Gansu were 9.35%(from 314 million yuan to 449 million yuan)and 36.05%(from 2.58×10^(8) to 8.84×10^(8));among which the average annual growth rate of the consumption sum in primary medical institutions was the highest,totally 17.98%(from 16 million DDDs to 31 million DDDs);and the average annual growth rate of the consumption sum in tertiary medical institutions was the lowest,totally 7.85%(from 170 million yuan to 230 million yuan).During the past five years,there were significant differences in the drug use structure index of diabetes drugs in medical institutions at all levels.CONCLUSIONS:There is a difference in the growth rate of total consumption sum and DDDs of diabetes drugs in Gansu,and the categories of diabetes drugs used in medical institutions at all levels have their own focus.Compared with 2018,the proportion of high-priced drugs used in medical institutions at all levels rises in 2022,most notably in primary medical institutions,and there is still a large upside in the standardization of drug use.Clinical rationalization of drug use should continue to be promoted to effectively control the growth of drug costs.
作者
何静
吴君桐
刘杰
陈永聪
马永恒
HE Jing;WU Juntong;LIU Jie;CHEN Yongcong;MA Yongheng(School of Public Health,Lanzhou University,Lanzhou 730000,China;Gansu Provincial Public Resource Trading Center,Lanzhou 730000,China)
出处
《中国医院用药评价与分析》
2024年第4期478-481,486,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
国家第六批药物集中带量采购政策控费效果研究(No.横20220401)。
